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Abstract
Background: Cord blood (CB) is a promising source for hematopoietic stem cell transplantations. The limitation of cell dose
associated with this source has prompted the ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs).
However, the expansion procedure is known to exhaust the stem cell pool causing cellular defects that promote apoptosis
and disrupt homing to the bone marrow. The role of apoptotic machinery in the regulation of stem cell compartment has
been speculated in mouse hematopoietic and embryonic systems. We have consistently observed an increase in apoptosis
in the cord blood derived CD34
+ cells cultured with cytokines compared to their freshly isolated counterpart. The present
study was undertaken to assess whether pharmacological inhibition of apoptosis could improve the outcome of expansion.
Methodology/Principal Findings: CB CD34
+ cells were expanded with cytokines in the presence or absence of cell
permeable inhibitors of caspases and calpains; zVADfmk and zLLYfmk respectively. A novel role of apoptotic protease
inhibitors was observed in increasing the CD34
+ cell content of the graft during ex vivo expansion. This was further reflected
in improved in vitro functional aspects of the HSPCs; a higher clonogenicity and long term culture initiating potential. These
cells sustained superior long term engraftment and an efficient regeneration of major lympho-myeloid lineages in the bone
marrow of NOD/SCID mouse compared to the cells expanded with growth factors alone.
Conclusion/Significance: Our data show that, use of either zVADfmk or zLLYfmk in the culture medium improves expansion
of CD34
+ cells. The strategy protects stem cell pool and committed progenitors, and improves their in vitro functionality and
in vivo engraftment. This observation may complement the existing protocols used in the manipulation of hematopoietic
cells for therapeutic purposes. These findings may have an impact in the CB transplant procedures involving a combined
infusion of unmanipulated and expanded grafts.
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Introduction
Cord Blood serves as an alternate source of hematopoietic stem
cells for patients with malignant and non malignant conditions for
whom HLA matched donors are not available. Cord blood
possesses several inherent advantages over the bone-marrow–
derived hematopoietic stem cells like the ease of procurement and
low risk of severe graft-versus-host disease (GVHD) [1]. Unfortu-
nately despite these attractive features, cord blood transplantations
for adult patients still lag behind due to a low number of nucleated
cells and CD34
+ cells within a single cord blood collection. Double
cord transplantation and a combined infusion of an unmanipulated
and an expanded graft have been tried in clinics to tackle this
problem [2,3,4,5]. Thus the strategies to expand either CD34
+ cells
or the selected subpopulations from cord blood are an area of active
research. Last few years witnessed various clinical trials in the
transplantation of expanded graft and have demonstrated the safety
and the feasibility of the expansion procedures [6,7,8,9]. However
in majority of cases the common problem confronted was the
altered behavior of the cultured hematopoietic stem/progenitor
cells (HSPCs) making the expanded graft less competent in
transplant settings. The expansion culture is known to cause several
cellular defects like loss of stem cells, down regulation of adhesion/
migration properties, reduced clonogenicity and initiation of
apoptosis [8]. This may render the already fewer stem cells
compromised causing an altered marrow engraftment. Some of the
earlier studies have pointed out the role of apoptosis cascade in
maintaining the stem cell compartment [10,11]. The role of two
cysteine proteases; caspase and calpain has been highly implicated
in programmed cell death in many cell systems [12,13].
The impact of apoptosis in the hematopoietic compartment has
been pointed out by Liu and colleagues as they demonstrated an
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+ cells were
transplanted into the SCID model due to the activation of the
apoptotic CD95 pathway [14]. Our previous studies also suggested
a negative impact of apoptosis on the behavioral aspects of frozen
mouse bone marrow cells [15]. The pan caspase inhibitor
zVADfmk is used in cryopreservation studies as well [16]. More
over, we have consistently observed a three to four fold increase in
apoptosis upon cytokine stimulation of CB derived CD34
+ cells
compared to their fresh counterparts.
Keeping these findings in mind, we hypothesized that the
prevention of apoptosis may play an important role during the ex
vivo expansion of HSPCs. To validate this hypothesis, we
employed a strategy of transient regulation of apoptosis by using
the cell permeable inhibitors of two major apoptotic proteases;
caspase and calpian as supplements to the cytokine containing
expansion medium. We observed a significant improvement in the
CD34
+ cell expansion upon protease inhibition. The expanded
graft also exhibited superior in vitro and in vivo functional
properties.
Our data reveals a novel role of apoptotic protease inhibitors in
stimulating hematopoiesis in vitro, thereby improving the quality
of expanded grafts. The observations herein may contribute to the
expansion protocols when used either singly or in conjunction with
other methods.
Results
Presence of zVADfmk and zLLYfmk improves the cell
yield and reduces apoptosis during ex vivo expansion
We observed a higher incidence of apoptosis, when the cord
blood derived CD34
+ cells were cultured with cytokines compared
to their freshly isolated counterparts (Figure S1). Thus we sought
to assess the role of cell permeable inhibitors of cysteine proteases;
caspase (zVADfmk) and calpain (zLLYfmk) as supplements in the
serum free culture of CD34
+ cells. We noticed that after the ex
vivo culture, the total cell yield increased up to 30–70 fold, relative
to the input cell number in all the three sets in various cord blood
units analyzed (data not shown). However, the presence of
zVADfmk or zLLYfmk resulted in a significantly higher cell yield
compared to the control on the 10
th day (Figure S2A, n=6).
Apoptosis in the culture was analyzed by a multiparametric
study combining the protein and transcript analysis. Annexin V
staining was carried out to detect the initial phase of apoptosis. A
shown in Figure 1A, there was a significant reduction in the
Annexin V+ population in the cells expanded with zVADfmk/
zLLYfmk compared to the control (p0.003, p0.002, n=5). We
further observed that both the caspase and calpain inhibitors
reduced the activation of caspases with an equal efficiency. The
presence of active downstream/executioner caspases viz caspase3/
7, was significantly reduced in the test sets as assessed from a cell
free cytosolic enzymatic assay (Figure 1B, p 0.010, p 0.017, n=4).
Similarly, the transcript level analysis showed a reduction in the
expression of major members of the apoptotic machinery. The
expression of various genes for caspase1, caspase 3 and caspase 8
was studied along with Fas antigen/CD95 (Figure 1C). There was
a 1.25 fold reduction in the ICE/casp1 mRNA in the test cells
compared to control. The caspase 3 mRNA was down regulated
1.3–1.5 times, whereas caspase 8 was down regulated by 1.5 times
in the test cells. The Fas/CD95 was down regulated 2 fold in the
cells expanded in presence of zVADfmk, and was reduced 2.75
times in the cultures expanded in the presence of zLLYfmk.
Reduction in the apoptosis was accompanied by an increase in
the bcl-2
+ population. Figure 1D depicts the representative
flowcytometry profile showing a higher bcl-2
+ population. Since
bcl-2 expression is known to augment the stem cell functionality,
we compared the control and zVADfmk/zLLYfmk cultured cells
that co express bcl-2 along with the CD34 marker. There was a
substantial increase in the number of bcl-2
+ cells within the CD34
compartment upon protease inhibition as revealed by a two colour
flowcytometry analysis (Figure S2B, n=4).
Presence of cysteine protease inhibitors favoured the
expansion of CD34
+ cells
The expansion efficiency mainly relies on the CD34
+ cell
content of the graft. The addition of zVADfmk or zLLYfmk
during the in vitro expansion significantly increased the total
CD34
+ cell content compared to the control (Figure 2A). More
over there was a 3 fold increase in the CD34
+CD38
2 cell content
in the presence of either the compounds (Figure 2A, n=5).The
surface CD34 expression at individual cell level was remarkably
increased in the test sets as confirmed from confocal laser
microscopy, implicating a role of these two compounds in the
modulation of CD34 turn over (Figure 2B, n=3).
To corroborate the above observation of enhanced generation
of CD34
+ cells in culture, we analyzed the relative abundance of
the gene expression of CD34 in the both the experimental
conditions. The quantitative real time PCR analysis revealed a
higher transcript level of CD34 in the presence of zVADfmk/
zLLYfmk compared to the control confirming the above
observations. (Figure 2C, n=3). These findings were noteworthy
as it unveiled a hitherto unknown role of two known apoptotic
inhibitors in regulating the CD34
+ population at both the protein
and transcript levels.
Apart from increasing the CD34 gene expression, the presence
of zVADfmk and zLLYfmk up regulated the notch receptor 1(3–5
fold), and its ligand jagged 1 (4–5 fold) which is one of the crucial
signaling pathway involved in the maintenance of stem cell
compartment in the hematopoietic system. These results indicated
that despite the conventional role of reducing the apoptosis level,
these compounds extended their function in positively regulating
the stem cell pool in the expanded cells by activating the notch
signaling. (Figure 2C, n=3).
The expanded HSPCs were predominantly myeloid
committed in nature
In order to check whether the incorporation of the protease
inhibitors leads to a proliferation associated differentiation, we
analyzed the expanded cells for the presence of lymphoid and
myeloid lineages. We observed that 50–70% the expanded CD34
+
cells co-expressed the myeloid marker CD33 and a remarkable
increase in the myeloid progenitor population (CD34
+CD33
+) was
observed in the zVADfmk/zLLYfmk cultured cells compared to
the control indicating the presence of more progenitor cells upon
protease inhibition (Figure 3A, p0.014, p0.049, n=3). Moreover,
the negligible percentage of CD34
+CD33
2 subset ruled out the
possibility of the binding of mature myeloid cells to CD34. This
was assessed by the double immunostaining of CD34
vs.CD33.The data further revealed that virtually all the cells
examined were CD34
+19
2 (B lymphoid) and CD34
+CD3
2 (T
lymphoid) after the culture period. Figure 3B depicts a
representative flowcytometry profile of the same.
Enhanced colony formation of the cells expanded in the
presence of protease inhibitors
In vitro colony formation reveals the presence of early progenitors
in the culture, which can differentiate into myeloid or lymphoid
colonies in the presence of a combination of growth factors. The
Expansion of CB CD34+ Cells
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+ cells expanded with and without apoptotic inhibitors were
seeded in semi solid methyl cellulose medium with the growth factor
combinations as described in methods. The multipotential differen-
tiation ability of HSPCs in the methyl cellulose assay showed a
significant increase in the total and differential colony formation in
the presence of either of the compounds compared to the control.
F i g u r e4 Ai st h em e a nd a t ao f4d i f f e r e n ts a m p l e ss h o w i n ga3 . 5f o l d
increase in the total CFU units in the zVADfmk/zLLYfmk sets.
(p0.042, p 0.03, n=4). Differential colony count of a representative
sample is shown in Figure 4B showing an increase in all the three
major colonies (Burst forming unit erythroid- BFU E, Granulocyte-
macrophage-megakaryocytes – GEMM and granulocyte-macro-
phage–GM) in the presence of inhibitors.
The cells expanded in the presence of protease inhibitors
contained higher number of Long term culture initiating
cells
The LTC system not only offers an approach to investigate the
proliferative and differentiative events, but also reflects the self-
renewal ability of HSCs. The expanded control and zVADfmk/
zLLYfmk exposed HSPCs were cultured on an irradiated
supportive stromal feeder layer for further five weeks followed
by colony forming assay. The cells expanded in the presence of the
compounds retained significantly higher number of primitive
population (LTC units) compared to the control sets. The data of a
representative sample is shown in Figure 4C.There was a 2.5–3.5
fold increase in the number of GM colonies in the cells expanded
Figure 1. zVADfmk and zLLYfmk reduced the level of apoptosis during ex vivo expansion. (A) The expanded control and zVADfmk/
zLLYfmk cells were assessed for the expression of pro and anti apoptotic molecules. Annexin V staining was carried out to detect the apoptotic
population. The percent annexinV
+ population decreased significantly when the CD34
+ cells were cultured in the presence of either of the protease
inhibitors showing a reduced level of apoptosis in the culture. Data represented as mean positive population 6 standard deviation from five
independent experiments n=5 (B) The presence of active caspases (Casp3/7) in the culture was assessed using a cell free cytosolic enzymatic assay
and the zVADfmk/zLLYfmk sets showed a significant reduction in the activity of these caspases as assessed from four different CB units. Data is
represented as mean 6 standard deviation. (n=4). (C) The transcript analysis of various pro apoptotic genes like caspase 1, caspase 3, caspase 8 and
CD95/Fas, revealed a reduction in their expression upon protease inhibition compared to the control. (D) The analysis for the presence of anti
apoptotic bcl-2 showed a significant increase in the cells expanded with zVADfmk/zLLYfmk. Representative flowcytometry profile is shown. (Black
line– Isotype, green line – control, pink line – zVADfmk and blue line- zLLYfmk respectively (n=4).
doi:10.1371/journal.pone.0012221.g001
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erythroid and CFU mix colonies whereas the control cells formed
only the GM colonies. The presence of GEMM colonies, in
comparison to the control, signifies the preservation of more
primitive cells in those sets. Similar increase in total LTC units was
observed with different expanded cord blood units (Figure S2C,
n=3).
Protease inhibition improved the engraftment of ex vivo
expanded HSPCs
To assess the in vivo engraftment ability of the expanded graft,
we intravenously administered the cultured control and test cells
into sub lethally irradiated NOD/SCID mice as described in
methods. 10
6 cells of the expanded end product were used for intra
venous infusion. The animals were sacrificed on 16
th week post
transplant and the level of human engraftment was assessed. The
percent engraftment in each set was compared to the PBS infused
irradiated recipient to detect the background staining if any. Both
the expanded control and zVADfmk/zLLYfmk expanded cells
engrafted the irradiated recipient. However, the animals, which
received the HSPCs, expanded in the presence of either of the
inhibitors showed a higher engraftment than the animals that
received the HSPCs expanded with growth factors alone. These
superior engraftment potential correlated well with the in vitro
results. Figure 5A shows the engraftment of huCD45 and huCD34
in the bone marrow of individual animals revealing the superior
potential of the zVADfmk/zLLYfmk expanded graft compared to
the standard cytokine expanded graft (p#0.001, p0.001).The
representative flow contour plots are shown in Figure S3A and
Figure S3B.The multilineage engraftment was assessed by using a
panel of antibodies against lympho-myeloid lineages. The presence
of zVADfmk or zLLYfmk was found to be beneficial in generating
a higher myeloid (CD33), megakaryocytic (CD41a) and lymphoid
(CD19) population in the bone marrow of the irradiated recipient
(Figure 5B). The representative flow contour plots are shown in
Figure S3C–E.
The presence of protease inhibitors in the media was also
beneficial for the expansion of frozen-thawed cord blood
units
Cord blood transplantations in the clinics mainly involve the use
of cryopreserved grafts. Our current observations with fresh cord
blood units clearly suggested that an optimized anti apoptotic
strategy in frozen units will have a significant and positive impact
during expansion, thereby potentially improving their clinical
utility. In order to test this hypothesis, we carried out the
expansion of frozen CD34
+ cells with and without the two
compounds and found that the two protease inhibitors were
equally effective. Apoptosis was found to be reduced in the
zVADfmk/zLLYfmk cultured cells. AnnexinV
+ population and
caspase-3 expression was reduced as shown in Figure 6A and
Figure 6B (n=3). Concomitantly a higher bcl-2 expression was
seen in those cells compared to the control (Figure 6C, n=3).
There was an increase in the CD34
+ cell content up to 3.5–4 fold
in the presence of zVADfmk/zLLYfmk relative to the control
(Figure 6D, n=3). The clonogenic potential was also assessed and
found to be significantly higher as shown in Figure 6E (n=4).
These observations prompted us to assess the possibility of
cryopreservation of the expanded HSPCs from fresh CD34
+ cells.
Post thaw analysis revealed a higher recovery of both viable and
nucleated cells from the cells expanded in the presence of these
compounds. The CD34
+ population was maintained to a
significantly higher extent along with the primitive CD34
+CD38
2
subset. This reflected in the higher colony formation and LTC
output (data not shown), thus underscoring the fact that the
beneficial effect of these two additives during expansion, persisted
even after the freezing stress.
Overall, our findings highlight the potential use of these two
compounds in the expansion protocols so as to yield a superior
quality graft which may benefit in transplant settings.
Discussion
Cord blood is an established source for stem cell transplantation
procedures. In contrast to marrow, CD34
+ cells from cord blood
possess higher proliferative potential, and a higher frequency of
long term and SCID repopulating cells [17]. However, the limited
number of cell dose in this source has prompted researchers to
develop alternative methods to increase the cell number. Ex vivo
expansion is one approach to increase the number in a clinically
relevant manner [18]. This strategy overcomes the limitation
posed by low cellularity of CB units for unrelated transplants in
adults. Development of reliable methods for the expansion of cord
blood stem cells is critical to ensure their further clinical
application. Many investigators have employed various methods
to expand the HSCs; either by genetic/epigenetic approaches or
by using specific compounds which affect self renewal pathways
[19,20,21,22]. Tanaka H et al. has used a Hox decoy peptide for
expansion and reported a nearly 2 fold increase in the CD34
+ cells
[20]. Use of valproic acid has also resulted in a 2 fold expansion of
CD34
+ cells as shown by Seet et al [22]. Recently Nishino and
colleagues have used a c- MPL agonist to expand the CD34 cells
[21]. Several groups have reported varying cell yield depending on
the source of isolated cells and the culture conditions [23,24] Ueda
and colleagues have amplified HSPCs in serum free medium and
found that the combination of SCF, TPO, Flt3-L IL-6 and IL-6-R
as growth factors was superior in expanding SRCs. They
demonstrate a 45 fold increase in total cell number [25]. We
report a 30–70 fold increase in total nucleated cell yield in all three
sets after ex vivo expansion using a similar combination of
cytokines used by Ueda et al except for IL-6R. However, the
concentrations used were much lower than those used by them.
The use of Stem pro media which is formulated to support the
amplification of HSCs might have also contributed for the robust
cell expansion even in control cells. [26] The experimental
‘control’ in our cultures, thus served as a normal expanded graft.
Keeping this ‘control’ as background we have further aimed to
increase the quality and functionality of the expanded HSPCs by
supplementation of apoptotic protease inhibitors.
Here we demonstrate for the first time that the reduction in the
level of apoptosis brought about by zVADfmk and zLLYfmk
Figure 2. Presence of cysteine protease in the culture favored the expansion of CD34
+ cells. (A) The expanded control and zVADfmk/
zLLYfmk exposed HSPCs were stained using anti human CD34 antibody and was quantitated by flowcytometry. The percent positive population was
normalized to the respective cell yield on the 10
th day (n=5). The CD34
+CD38
2 cell content of the expanded test HSPCs was significantly increased.
(B) Collected HSPCs were immunostained using anti human CD34 antibody and analyzed by confocal microscopy. There was a remarkable increase in
the CD34 intensity when the cells were expanded in the presence of the protease inhibitors showing that the inclusion of these compounds
increased the basal CD34 expression. Bar=10 mm. (C) Quantitative real-time analysis showing a higher gene expression of CD34, notch1 and jagged 1
in the test expanded HSPCS relative to the control.
doi:10.1371/journal.pone.0012221.g002
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+ cell
content and enhances the functional properties of the graft. The
maintenance of HSCs requires the coordination of complex
pathways that involve control of self-renewal, differentiation and
apoptosis as reviewed by Alenzi et al [27]. Of note, Hatzold and
colleagues have revealed a striking functional link between
apoptosis and asymmetric cell division in C.elegans [28]. Their
studies point out to an evolutionary conserved role of apoptosis in
stem cell biology. Furthermore another body of research
highlighted that the over expression of anti apoptotic bcl-2
maintained the mouse embryonic stem cells in an undifferentiated
state in a feeder free condition [29]. Domen and colleagues have
shown that a block in apoptosis has increased the HSC pool in bcl-
2 transgenic mice [10]. An elegant work by Imai et al in murine
system showed that the use of zVADfmk facilitated the
engraftment of mouse marrow cells in an intra bone marrow
transplantation [30]. These evidences link the negative regulation
of apoptosis with the maintenance of stem cell pool.
Figure 3. Lineage assessment of the expanded HSPCs. (A)The expanded HSPCs were double immunostained with CD34 vs. lineage antibodies
like CD33 (myeloid) CD19 (B lymphoid) and CD3 (T lymphoid) cells. 50–70% of cells comprised of CD34
+CD33
+ myeloid with a negligible percentage
of CD34+CD19
+ and CD34
+CD3
+ cells. The zVADfmk/zLLYfmk expanded cells showed a significant increase in the CD34
+CD33+ subset as compared
to the control. (B) Representative flowcytometry profile showing the double Immunostaining of CD34 vs CD33, CD19 and CD3.
doi:10.1371/journal.pone.0012221.g003
Figure 4. Improved CFU and LTC output of the expanded HSPCs. The in vitro functional properties of the expanded HSPCs significantly
improved upon protease inhibition. (A) Colony formation assay on a semi- solid methyl cellulose media was carried out. After 14 days of incubation,
the three major colonies (BFU- E, GM, and GEMM) were scored under an inverted microscope. The total colonies were normalized to the cell yield.
There was a 3.5 fold increase in total progenitors in the cells expanded in the presence of zVADfmk and zLLYfmk. Data are represented as mean 6
standard deviation of four different CB samples (n=4). (B) A representative data showing the presence of differential colonies: BFU E, GM and GEMM
formed in the three sets. (C) LTC assay was carried out to assess the presence of more primitive stem cells within the cultured HSPCs. At the end of
fifth week, the adherent and non adherent cells were pooled and subjected to colony formation and the major colonies formed were scored. The
cells expanded in the presence of either of the protease inhibitors preserved the LTC units to a higher extent. There were no BFU-E and GEMM
colonies in the control. The zVADfmk/zLLYfmk sets formed both BFU-E and GEMM in addition to GM colonies. Data from a representative experiment
is shown (n=3).
doi:10.1371/journal.pone.0012221.g004
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PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12221Figure 5. In vivo engraftment of the expanded HSPCs in NOD/SCID mice. (A) The SRC (Scid Repopulating Cells) efficiency of the cultured
HSPCs was assessed in NOD/SCID mouse model. The expanded cells were intravenously administered to the sub lethally irradiated recipient. After
16th week (4 months), the animals were sacrificed and the bone marrow cells were stained for human pan leukocyte marker CD45 and progenitor
marker CD34. The presence of zVADfmk/zLLYfmk in the expansion culture proved to be more efficient in repopulating the marrow compared to the
control as there was a significantly higher engraftment detected by huCD45 and huCD34 (B) Multilineage engraftment potential of the zVADfmk/
zLLYfmk expanded cells was superior to their control counterparts as detected from the presence of huCD33, huCD41a and huCD19 in the bone
marrow of recipient mice. Data represented as mean 6 standard deviation (n=3).
doi:10.1371/journal.pone.0012221.g005
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+ cells also
indicate that a similar regulatory role of apoptosis exists in the
human progenitor compartment as well. The supplementation of
the expansion media with the protease inhibitors, did not cause an
enhanced differentiation, but preferentially expanded the CD34
+
population, overcoming the major hurdle in the expansion
protocols. CD34 expression assessed by confocal microscopy
revealed that both surface and cytoplasmic pattern (data not
shown) of CD34 existed. However the intensity was consistently
higher in test sets as described in results. Higher CD34
+ cell
content is important in the light of transplantation settings.
Moreover we observed a three fold increase in CD34
+CD38
2 cell
content during expansion in the presence of either of the
compounds. Since the regulation of apoptosis cascade was a
transient phase in our studies, the DNA damaged cells are
expected to die off after the withdrawal of inhibitors. Thus the
survival of abnormal stem cells which may be a concern from the
translation point of view may be minimal in our cultures. However
further studies are required to address this possibility.
Earlier studies have shown the significance of notch, and its
ligands, in the expansion and self renewal of HSPCs [31,32]. The
recent preclinical and clinical observations by Delaney et al
revealed that notch mediated expansion results in marked increase
in the stem/progenitor cells and the SRCs [33]. Our observation
of the up regulation of gene expression of the notch receptor and
its ligand jagged 1 suggested that the addition of these two
compounds during expansion, activated the notch signalling
molecules. In this context, it would be interesting to explore the
other signalling pathways also which has a direct role in the
regulation of the stem cell pool.
The increased bcl-2 expression evident in zVADfmk/zLLYfmk
sets is functionally relevant as bcl-2 has been reported to augment
the stem cell functionality [34]. Janzen et al have shown that
caspase-3 null mice harbour long term hematopoietic stem cells to
a higher extent compared to the wild type animal [35]. The
negative regulation of caspases has also been shown to be
necessary for the pluripotent state of embryonic stem cells [36].
All these observations speculated a possible role of caspases and
other cysteine proteases in the maintenance of stem cell turn over.
We demonstrate that the increased expansion efficiency of cord
blood CD34
+ cells in the presence of anti apoptotic agents was
associated with a concomitant reduction in the activity of major
caspases. The down regulation of Fas antigen is relevant here as it
is shown to inversely correlate with the homing efficiency of
CD34
+ cells [14]. More over, Bryder D et al have demonstrated a
negative impact of Fas mediated apoptosis in the self renewal of
hematopoietic stem cells [11]. However, whether there is a
possibility of faster senescence/shorter life time due to a higher
proliferation rate (upon apoptosis inhibition) needs to be further
looked into.
We further show the beneficial effect of protease inhibition on
the functional properties of the expanded cells. The multipotent
colony forming ability of the test cells was remarkably higher
compared to the control sets as assessed by colony formation and
LTC assays. The immature population of GEMM colonies
increased significantly in both the assays indicating an increased
survival and preservation of stem cells in the expanded test sets.
Our experiments with frozen thawed cord blood units demon-
strated the equal effectiveness of these compounds during the in
vitro expansion underscoring their clinical utility.
Expansion has been reported to compromise on the engraftment
potential of HSCs. Expansion of both HSCs and HPCs are
essential, since the committed progenitors give rise to an immediate
short term engraftment where as the primitive HSCs in the graft
sustain hematopoiesis throughout [37]. The myeloid restricted
HSPCs are critical for the initial phase of clinical transplantation as
observed by severalinvestigators[17,38]. The end product of our ex
vivo cultureswerepredominantlymyeloid committedinnaturewith
a significantly higher CD34
+ cell content in the presence of
zVADfmk/zLLYfmk which resulted in an improved engraftment in
animals that received those grafts (.0.1% positive human cells were
considered as a cut off for engraftment as per Mattia et al [39] ).The
presence of lymphoid (huCD19) engraftment in the bone marrow
using cord blood expanded HSPCs are reported by a few
investigators [25,40]. In our studies, the engraftment in NOD/
SCID mice was carried out for a period of 16 weeks, which is a
permissive duration for the lymphoid engraftment to be seen, albeit
less prominent compared to the engraftment detected by huCD45
and huCD34 markers. The higher number of immature GEMM
(CFU mix) colony formation ex vivo upon protease inhibition, very
well translated in regenerating a higher multilineage engraftment in
NOD/SCID mice.
Taken together our results unveil a novel role of two apoptotic
inhibitors; zVADfmk and zLLYfmk in stimulating hematopoiesis
in vitro and improving the engraftment potential in vivo, making
the expanded graft superior to the cytokine cultured HSPCs. Our
findings may help in adding a further step in refining the
expansion protocols to yield a graft competent in transplant
settings.
Methods
Collection of Umbilical cord blood and isolation of CD34
+
cells
Cord blood samples were collected from local hospitals with
written informed consent from the mother. The institutional review
board (IEC-Institutional ethical committee, NCCS) approved
protocols for the uses of human samples were followed. Mononu-
clear cells were separated from the cord blood by ficoll hypaque
(density 1.077 g/ml, Sigma Aldrich, St.Louis MO) density gradient
centrifugation. CD34
+ cells were isolated from the mononuclear
cells using Dynal beads as per manufacturer’s instructions
(Dynabeads M-450 CD34; Dynal, ASA, Oslo, Norway).
Ex vivo expansion of CD34
+ cells in serum free medium
CD34
+cells were seeded at a density of 5610
4 cells/well/500 ml
of Stempro medium (GIBCO, Grand Island, NY), in 24 well
Figure 6. The presence of protease inhibitors in the media was also beneficial for the expansion of frozen-thawed CB units. (A)
Representative flowcytometry profile showing a reduced number of Annexin V
+ population when the frozen CD34
+ cells were expanded in the
presence of either of the compounds, n=3. (B) The cytosolic caspase 3 expression was remarkably reduced in the zVADfmk/zLLYfmk sets compared
to the control counterpart as analysed by confocal microscopy. (C) Concomitantly the bcl-2 expression in those cultures increased relative to the
control, showing a reduction in the apoptosis cascade. Results presented are representative fields confirmed from at least 3 different samples.
Bar=10 mm. (D) The percent CD34
+ population was quantified by FACS and it was observed that CD34
+ cell content increased (3.5–4 fold) fold when
the frozen thawed CB units were expanded in the presence of either of the compounds (n=4). (E) The clonogenic potential of the test expanded cells
showed a significant increase in the differential colony formation. The presence of GEMM colonies were remarkably higher compared to the control
frozen cells. Data of a representative experiment is shown (n=4).
doi:10.1371/journal.pone.0012221.g006
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were from Peprotech Inc, Rocky Hill, NJ) were used at a final
concentration of 25 ng/ml with (test cells) and without (control
cells) the addition of either zVADfmk -100 nM or the zLLYfmk
10 mM (MP Biomedicals, Aurora, Ohio). Cells were cultured for
10 days and were collected from the suspension cultures and
centrifuged (1000 rpm for 5minutes). Further the cells were
quantitated for expansion and apoptosis by various methods.
After expansion, these cells were either used for assessing the
invitro functionality by CFU, and LTC assay or were used for in
vivo engraftment in NOD/SCID mice. Thus in vitro and in vivo
studies were carried out using independent CB units.
Flowcytometry analysis
Phenotypic analyses of the expanded cells were carried out at
the 10
th day. Cells were analyzed for the expression of surface
markers like Annexin V, CD34, CD38, Bcl-2, CD33, CD19 and
CD3 (BD pharmingen- San Jose, California). The expanded
control and treated cells were collected and suspended in 1xPBS
containing 0.1% BSA. After the addition of antibodies the cells
were incubated for 40 min on ice. Excess antibody was removed
by washing with PBS and the cells were fixed using 1%
paraformaldehyde solution and kept at 4uC till acquiring.
Intracellular bcl-2 expression was analysed using hamster anti
human antibcl-2 antibody (Beckton Dickinson; San Jose, Califor-
nia). For this the cells were fixed and permeabilized using BD
fixperm kit (BD pharmingen -San Jose, California) and the
staining was done as per manufacturer’s instructions. Appropriate
isotype controls were kept for each set. For Annexin V staining,
the washed cells were suspended in 16Binding buffer and 5 mLo f
Annexin V FITC, (BD pharmingen -San Jose, California) for 15
minutes at room temperature. 10 ml of PI solution was then added
and analysed by flowcytometry. Total cells in the FSC and SSC
pattern were gated after excluding the debris. A minimum of
10,000 events were for each sample on either FACS CantoII
(Beckon Dickinson San Jose California) using FACS Diva software
or on FACS Calibur (Beckon Dickinson San Jose California) using
cell quest pro software.
Immunofluorescence and Confocal microscopy
Ex vivo expanded HSPCs were analyzed for the expression of
CD34 and the apoptosis related proteins like caspase 3 and bcl-2.
Mouse antihuman CD34 antibody (BD pharmingen, San Jose,
California), mouse antihuman bcl-2 and rabbit anti human
caspase-3 (Santacruz biotech, Santacruz, CA, USA) antibodies
were used at 1:50 dilutions. Goat anti rabbit polyclonal IgG FITC
and goat anti mouse monoclonal IgG FITC (BD pharmingen, San
Jose, California) were used at 1:100 dilution. Cells were fixed in
4% paraformaldehyde, permeabilized with chilled 50% methanol
(as per requirement) and blocked with PBS containing 1% BSA for
1 hour. Primary antibodies were incubated overnight at 4uC,
washed with PBS and then incubated with the secondary
antibodies at room temperature for 1 hour. Slides were washed
in PBS twice and mounted in mounting medium. Confocal images
were obtained using a Zeiss LSM 510 laser scanning microscope.
Results presented are representative fields confirmed from a
minimum of 3 different biological samples.
Cellular Caspase 3/7 activity assay
After 10 days of culture, the control and the zVADfmk/
zLLYfmk exposed cells were collected and were subjected to lysis
to obtain the cell free cytosolic fraction, as per the assay kit
instructions. The Z-DEVD-R110 substrate based assay was
carried out as per the manufacturer’s instructions (Molecular
Probes, Eugene, Oregon, USA).
Reverse Transcription Polymerase chain reaction
mRNA was isolated from the expanded cells using Dynabeads
mRNA DIRECT kit as per the manufacturers instructions
(Invitrogen, Dynal ASA, oslo Norway). The eluted mRNA were
reverse transcribed to cDNA by using reverse transcriptase (Sigma
Aldrich, St Loius, MO) and oligo-dT primers (invitrogen) as per
the instructions and PCR was performed with specific primers.
The thermal cycle used was (95uC for 2 min, 95uC for 45 sec,
annealing (as per different genes) for 45 sec, extension 72uC for
2 min) for 35 cycles and a final extension at 72uC for 5 minutes.
The amplified product was run in 2% agarose gel and stained with
EtBr (Ethidium bromide). The images were captured in a gel
documentation system (Syngene Ingenius, NJ 08830, USA). The
densitometric quantification of the amplified PCR products were
done using Quantity One software (BioRad, Philadelphia, PA).
The primer sequences used were as described in Figure S4.
RNA isolation and Real-time PCR analysis
Total RNA was isolated using Trizol reagent (Sigma Aldrich, St
Loius MO) as per manufacturer’s instructions. The isolated RNA
was quantitated using nanodrop spectrophotometer (ND1000).
First strand cDNA synthesis was carried out by using ‘high
capacity cDNA archive kit’ (Applied Biosystems, Foster City, CA)
with random hexamers. 1 mg RNA of each sample was reverse
transcribed to cDNA in 10 ml of final volume. 1 ml of the prepared
cDNA was used for real-time PCR of each gene. The real time
PCR was performed using the SYBR-Green PCR master mix
(Applied Biosystems, Foster City, CA) and specific gene primers in
a 7500 ABI-prism sequence detection system (Applied Biosys-
tems).The final reaction volume for real time PCR was 20 ml for
each gene and the thermal cycle used was 50uC for 2 min, 95uC
for 10 min, (95uC for 15 sec, 60uC for 1 min) for 40 cycle.
Samples without reverse transcription were used as negative
controls. All qRT-PCR values were normalized to 18 s and
calculated according to manufacturer’s instructions.
Colony Forming Unit assay
CFU assays were performed using the semisolid methyl cellulose
media as described earlier [41]. After 14 days of culture, colony
forming unit of Granulocytes-Macrophages (CFU-GM), Burst
Forming Unit Erythroids (BFU-E), and mixed colonies of
Granulocyte- Erythroid-Macrophage- Megakaryocytes (GEMM)
were scored under an inverted microscope.
Establishment of long term cultures
The LTC system allows the detection of very primitive HSPCs
in the culture system. The LTC assay was carried out as described
earlier [42]. After the 5 week culture period, the non-adherent and
the adherent fractions were pooled and then were subjected to the
colony formation assay.
Engraftment of expanded cells in NOD-SCID mice
The NOD/LtSZ-scid/scid mice were obtained from Jackson
Laboratories (The Jackson laboratory, 610 St.Bar Harbor, Maine
04609, USA) and were bred in the animal facility of our institute.
The study was conducted adhering to the institution’s guidelines
for animal husbandry and has been approved by IAEC-NCCS/
CPCSEA (Institutional animal ethical committee-NCCS/Com-
mittee for the Purpose of Control and Supervision of Experiments
on Animals. Approval number: IACUC-Institutional Animal Care
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71). Animal procedures involving intra-venous infusion were
carried out under anesthesia causing minimal pain and distress to
the animals. The approved protocol did not prohibit the use of
anesthesia. During the experimentation period the animals were
supervised under trained personals taking utmost care.
Mice at 4–6 weeks of age were exposed to sub lethal dose of 300
rads total body irradiation from a
60Co source (Gammachamber
5000, BRIT, Navi Mumbai, India). 10
6 expanded cells from each
set were mixed with an equal proportion of irradiated supportive
cells taken from CD34 depleted fraction of non cultured cells, and
were infused through the tail vein into the sub lethally irradiated
mice (n=3). Mice were sacrificed at 16
th week post transplant to
assess the human engraftment.
The human engraftment in the bone marrow was detected by
using huCD45 (pan hematopoietic) and huCD34 (stem/progenitor
cells). The multilineage engraftment in the bone marrow was
assessed by immunostaining the BM cells with a panel of
antibodies against human lineage markers comprising CD33
(myeloid), CD41a (megakaryocyte), and CD19 (B lymphoid). All
antibodies were purchased from BD pharmingen (Beckton
Dickinson; San Jose, California).The cells were blocked with
mouse IgG (Fc blocker) for 10 min at 4uC to reduce the non
specific binding and were then incubated with the antibodies along
with their respective isotype controls for 45 min at 4uC. In each
experiment, one group of animals were kept which were irradiated
and infused with PBS to detect the non specific background
staining. RBCs were lysed with Lysis Buffer (Beckton Dickinson,
San Jose, California) and the cells were washed twice with 16PBS
containing 0.1% BSA. The cells were then fixed using 1%
paraformaldehyde in PBS and a minimum of 50,000 events were
acquired on FACS CantoII (Beckton Dickinson, San Jose,
California).
Statistical analysis
The statistical differences between groups were analysed by one
way repeated measure analysis of variance using the software
SIGMA STAT (Jandel Scientific Corporation, San Rafael, CA) for
all the experiments. All comparisons were between control vs
zVADfmk and control vs zLLYfmk. The values were plotted as
mean 6 standard deviation Probability value: *p#0.05,
**p#0.01, & ***p#0.001 were considered statistically significant.
Supporting Information
Figure S1 Apoptosis analysis of unexpanded and expanded
HSPCs. Apoptosis was compared in the freshly isolated cord blood
derived CD34+ cells to their cytokine cultured counterpart. The
AnnexinV+ cells (apoptotic) increased 3–4 folds in the cultured
counterpart implicating a higher incidence of apoptosis when the
cells were cultured with growth factors alone in a serum free
condition. An identical FSC/SSC gating strategy was followed for
all samples on both day 0 and day 10.
Found at: doi:10.1371/journal.pone.0012221.s001 (0.98 MB TIF)
Figure S2 Higher cell yield, bcl-2 expression and LTC output
upon protease inhibition. (A) The total nucleated cell yield after
the exvivo expansion. The presence of zVADfmk and zLLYfmk
showed a higher cell yield compared to the control. Data are
represented as mean 6 standard deviation (n=6) (B) Two colour
flowcytometry analysis revealed the presence of a higher number
of bcl-2+ cells in the CD34 compartment of the total HSPCs. The
expanded HSPCs were immunostained for CD34. The stained
cells were fixed and permeabilized and counter stained with anti
bcl-2 antibody and analysed on FACS. The profile shows the
percent bcl-2+ cells in the gated CD34 population. (C) Table
summarizes the data of total LTC units formed from cultured
control and test HSPCs, assessed from three different cord blood
units. The total LTC output was significantly higher when the
CD34+ cells were expanded in the presence of either of the anti
apoptotic compound, revealing the presence of primitive stem cells
in them. Data is represented as mean 6 standard deviation (n=3).
Found at: doi:10.1371/journal.pone.0012221.s002 (2.79 MB TIF)
Figure S3 Human multilineage engraftment in the bone marrow
of NOD/SCID mice. (A–B) Representative flowcontour plots
showing the presence of higher huCD45 and huCD34 engraft-
ment in the marrow of mice that received the cells cultured in the
presence of zVADfmk/zLLYfmk (C–E) The human myeloid
(CD33), megakaryocyte (CD41a) and B lymphoid (CD19)
engraftment in the bone marrow.
Found at: doi:10.1371/journal.pone.0012221.s003 (1.30 MB TIF)
Figure S4 Primer sequences used for PCR analysis. Table
summarizes the list of the primer sequences used to perform the
PCR reaction.
Found at: doi:10.1371/journal.pone.0012221.s004 (0.64 MB TIF)
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